Cancer Council Victoria | Victorian Cancer Trials Link

A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Imatinib Combined With Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)

Clinical summary

You may be eligible for this study if you have newly diagnosed, Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia (PH+ALL).
Eligible participants will be randomly allocated to one of two treatment arms.
In the Experimental Arm, participants will receive Olverembatinib, orally once daily, in combination with chemotherapy.
In the Active Comparator Arm, participants will receive Imatinib, orally once daily, in combination with chemotherapy.

Conditions

This trial is treating patients with Philadelphia chromosome positive acute lymphoblastic leukaemia

Trial Acronym

Trial Identifiers
NCT06051409
HQP1351AG301

Cancer
Acute Lymphoblastic Leukaemia/Lymphoma (ALL), Leukaemia

Age: 18+
Phase: III

For full trial details, visit trials.cancervic.org.au/details/vctl_nct06051409